| COMMON STOCKST, MANY | Shares | Value |
|---|----------------|----------------------------|
| COMMON STOCKS [†] - 99.8% Pharmaceuticals - 31.5% | | |
| Eli Lilly & Co. | 972 \$ | 757,703 |
| Johnson & Johnson AbbVie, Inc. | 3,751 2,894 | 572,965 537,184 |
| Merck & Company, Inc. | 5,240 | 414,798 |
| Pfizer, Inc. | 14,332 | 347,408 |
| CVS Health Corp. McKesson Corp. | 4,153 390 | 286,474 285,784 |
| Bristol-Myers Squibb Co. | 6,030 | 279,129 |
| Zoetis, Inc. Cencora, Inc. — Class A | 1,477 749 | 230,338 224,588 |
| Becton Dickinson & Co. | 1,216 | 209,456 |
| AstraZeneca plc ADR | 2,892 | 202,093 |
| Cardinal Health, Inc. Dexcom, Inc.* | 1,146 | 192,528 |
| Novo Nordisk A/S ADR ¹ | 2,078 2,371 | 181,389 163,646 |
| Jazz Pharmaceuticals ple* | 1,427 | 151,433 |
| Novartis AG ADR | 1,198 | 144,970 |
| Teva Pharmaceutical Industries Ltd. ADR* | 8,421 | 141,136 |
| GSK plc ADR ¹ | 3,499 | 134,362 |
| Alkermes plc* | 4,479 | 128,144 |
| Neurocrine Biosciences, Inc.* | 843 10,811 | 105,957 |
| Viatris, Inc. Henry Schein, Inc.* | 1,159 | 96,542 84,665 |
| Corcept Therapeutics, Inc. * | 1,081 | 79,345 |
| Option Care Health, Inc.* | 2,143 | 69,605 |
| Vaxcyte, Inc.* | 1,809 | 58,811 |
| Madrigal Pharmaceuticals, Inc.* | 123 | 37,225 |
| Total Pharmaceuticals | | 6,117,678 |
| Healthcare-Products - 29.3% Abbott Laboratories | 3,386 | 460,530 |
| Abbott Laboratories Intuitive Surgical, Inc.* | 3,386 804 | 436,902 |
| Boston Scientific Corp. * | 3,720 | 399,565 |
| Chermo Fisher Scientific, Inc. | 906 | 367,347 |
| Stryker Corp. | 919 | 363,584 |
| Danaher Corp. Medtronic plc | 1,711 2,512 | 337,991 218,971 |
| Edwards Lifesciences Corp.* | 2,629 | 205,614 |
| IDEXX Laboratories, Inc. | 373 | 200,055 |
| ResMed, Inc. | 728 | 187,824 |
| Agilent Technologies, Inc. GE HealthCare Technologies, Inc. | 1,475 2,350 | 174,065 174,064 |
| STERIS plc | 607 | 145,813 |
| Natera, Inc.* | 861 | 145,457 |
| insulet Corp.* | 459 | 144,209 |
| Waters Corp.* | 386 | 134,729 |
| Zimmer Biomet Holdings, Inc. West Pharmaceutical Services, Inc. | 1,399 537 | 127,603 117,496 |
| Baxter International, Inc. | 3,876 | 117,365 |
| Cooper Companies, Inc.* | 1,602 | 113,998 |
| Hologic, Inc.* | 1,749 | 113,965 |
| Align Technology, Inc.* | 597 | 113,030 |
| Exact Sciences Corp.* | 1,797 | 95,492 |
| Avantor, Inc. * | 6,600 | 88,836 |
| Masimo Corp.* Bio-Techne Corp. | 527 1,651 | 88,652 84,944 |
| Lantheus Holdings, Inc.* | 870 | 71,218 |
| Merit Medical Systems, Inc.* | 757 | 70,764 |
| Repligen Corp.* | 568 | 70,648 |
| Bruker Corp. | 1,538 | 63,366 |
| TransMedics Group, Inc.* | 461 | 61,779 |
| Dentsply Sirona, Inc. | 3,353 | 53,246 |
| PROCEPT BioRobotics Corp.* Twist Bioscience Corp.* | 882 1,259 | 50,803 46,319 |
| Tandem Diabetes Care, Inc.* | 1,717 | 32,005 |
| Total Healthcare-Products | 1,717 | 5,678,249 |
| Biotechnology - 21.1% | | |
| Amgen, Inc. Gilead Sciences, Inc. | 1,282 3,199 | 357,947 354,673 |
| Vertex Pharmaceuticals, Inc. * | 712 | 316,982 |
| Regeneron Pharmaceuticals, Inc. | 427 | 224,175 |
| Alnylam Pharmaceuticals, Inc.* | 617 | 201,198 |
| CRISPR Therapeutics AG ^{*,1} | 3,173 | 154,335 |
| Argenx SE ADR* | 252 | 138,908 |
| BioNTech SE ADR*,1 | 1,288 | 137,133 |
| nsmed, Inc.* Royalty Pharma plc — Class A | 1,306 3,606 | 131,436 129,924 |
| Siogen, Inc. * | 1,005 | 126,218 |
| llumina, Inc.* | 1,261 | 120,312 |
| Inited Therapeutics Corp.* | 373 | 107,182 |
| xelixis, Inc.* | 2,391 | 105,383 |
| ncyte Corp.* | 1,450 | 98,745 |
| BioMarin Pharmaceutical, Inc.* | 1,735 | 95,373 |
| foderna, Inc.* | 3,415 | 94,220 |
| Blueprint Medicines Corp. * | 675 | 86,522 |
| Bridgebio Pharma, Inc.* | 1,957 | 84,503 |
| onis Pharmaceuticals, Inc.* | 1,989 | 78,585 |
| Guardant Health, Inc.* | 1,497 | 77,904 |
| Ialozyme Therapeutics, Inc.* | 1,434 | 74,597 72,506 |
| egend Biotech Corp. ADR* | 2,043 | 72,506 |
| evolution Medicines, Inc.* | 1,953 | 71,851 |
| G Therapeutics, Inc. * Roivant Sciences Ltd. * | 1,862 5,654 | 67,013 |
| | · | 63,721 58,481 |
| | | 3X 4X I |
| Cytokinetics, Inc.* | 1,770 3 163 | |
| Cytokinetics, Inc.* ADMA Biologics, Inc.* | 3,163 | 57,598 |
| Cytokinetics, Inc.* ADMA Biologics, Inc.* SpringWorks Therapeutics, Inc.* Axsome Therapeutics, Inc.* | | 57,598 56,012 52,717 |

| Viking Therapeutics, Inc.* | 1,846 | 48,919 |
|-----------------------------------|-------|-----------|
| Krystal Biotech, Inc.* | 326 | 44,812 |
| Crinetics Pharmaceuticals, Inc.* | 1,479 | 42,536 |
| Apellis Pharmaceuticals, Inc.* | 2,291 | 39,657 |
| Novavax, Inc.*,1 | 4,389 | 27,651 |
| Sarepta Therapeutics, Inc.* | 1,514 | 25,889 |
| Iovance Biotherapeutics, Inc. *,1 | 7,906 | 13,598 |
| Total Biotechnology | | 4,090,705 |
| Healthcare-Services - 15.7% | | |
| UnitedHealth Group, Inc. | 1,602 | 499,776 |
| Cigna Group | 878 | 290,249 |
| Elevance Health, Inc. | 730 | 283,941 |
| HCA Healthcare, Inc. | 644 | 246,716 |
| ICON plc* | 1,175 | 170,904 |
| Humana, Inc. | 681 | 166,491 |
| Centene Corp.* | 2,884 | 156,544 |
| IQVIA Holdings, Inc.* | 978 | 154,123 |
| Labcorp Holdings, Inc. | 543 | 142,543 |
| Quest Diagnostics, Inc. | 755 | 135,621 |
| Tenet Healthcare Corp.* | 703 | 123,728 |

Value

Shares

| | | Sinteres | | Turue |
|--|----|----------|----|------------|
| COMMON STOCKS [†] - 99.8% (continued) | | | | |
| Healthcare-Services - 15.7% (continued) | | | | |
| Molina Healthcare, Inc.* | | 412 | \$ | 122,735 |
| Universal Health Services, Inc. — Class B | | 566 | | 102,531 |
| HealthEquity, Inc.* | | 865 | | 90,617 |
| Ensign Group, Inc. | | 582 | | 89,779 |
| Charles River Laboratories International, Inc.* | | 539 | | 81,782 |
| DaVita, Inc.* | | 505 | | 71,937 |
| Medpace Holdings, Inc.* | | 226 | | 70,932 |
| Acadia Healthcare Company, Inc.* | | 1,930 | | 43,792 |
| Total Healthcare-Services | | | | 3,044,741 |
| Software - 1.7% | | | | |
| Veeva Systems, Inc. — Class A* | | 691 | | 198,994 |
| Tempus AI, Inc.*,1 | | 1,177 | | 74,787 |
| Waystar Holding Corp.* | | 1,466 | | 59,915 |
| Total Software | | | | 333,696 |
| Internet - 0.5% | | | | |
| Hims & Hers Health, Inc.*,1 | | 1,739 | | 86,689 |
| Total Common Stocks | | | | |
| (Cost \$11,775,101) | | | | 19,351,758 |
| Provinciti A AA | | | | |
| RIGHTS ^{†††} - 0.0% Pharmaceuticals - 0.0% | | | | |
| Johnson & Johnson | | | | |
| Expires 12/31/29 | | 752 | | _ |
| Total Rights | | 752 | | |
| (Cost \$-) | | | | _ |
| | | | | |
| | | Face | | |
| ++ 1 | | Amount | | |
| REPURCHASE AGREEMENTS ^{††,2} - 0.6% | | | | |
| J.P. Morgan Securities LLC issued 06/30/25 at 4.37% | | | | |
| due 07/01/25 | \$ | 61,364 | | 61,364 |
| Barclays Capital, Inc. | Ψ | 01,501 | | 01,501 |
| issued 06/30/25 at 4.39% | | | | |
| due 07/01/25 | | 26,478 | | 26,478 |
| BofA Securities, Inc. | | | | |
| issued 06/30/25 at 4.37% | | 25.569 | | 25.560 |
| due 07/01/25 | | 25,568 | | 25,568 |
| Total Repurchase Agreements (Cost \$113,410) | | | | 113,410 |
| (Cost \$113,410) | | | | 113,410 |
| | | Shares | | |
| SECURITIES LENDING COLLATERAL ^{†,3} - 3.1% | | | | |
| Money Market Fund*** | | | | |
| First American Government Obligations Fund - Class X, 4.25% ⁴ | | 601,714 | | 601,714 |
| Total Securities Lending Collateral | | | | |
| (Cost \$601,714) | | | | 601,714 |
| Total Investments - 103.5% | | | | |
| (Cost \$12,490,225) | | | \$ | 20,066,882 |
| Other Assets & Liabilities, net - (3.5)% | | | \$ | (672,038) |
| Total Net Assets - 100.0% | | | 3 | 19,394,844 |
| | | | | |

 $Non-income\ producing\ security.$

ADR — American Depositary Receipt plc — Public Limited Company

A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov. Value determined based on Level 1 inputs.

Value determined based on Level 2 inputs.

^{†††} Value determined based on Level 3 inputs.

All or a portion of this security is on loan at June 30, 2025.

Repurchase Agreements.

Securities lending collateral.

Rate indicated is the 7-day yield as of June 30, 2025.